Case History: A 55-year-old female presented with complaints of progressive dyspnoea with dry cough for more than one year. She has a past history of pulmonary tuberculosis six years ago for which she received treatment and was sputum negative after that. She had severe breathlessness and was intubated for the same during her present admission. Chest CT was done.
[[{"type":"media","view_mode":"media_crop","fid":"12225","attributes":{"alt":"","class":"media-image","id":"media_crop_1330432748319","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"385","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
[[{"type":"media","view_mode":"media_crop","fid":"12226","attributes":{"alt":"","class":"media-image","id":"media_crop_9598340601883","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"391","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
[[{"type":"media","view_mode":"media_crop","fid":"12232","attributes":{"alt":"","class":"media-image","id":"media_crop_966780433998","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"392","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
[[{"type":"media","view_mode":"media_crop","fid":"12233","attributes":{"alt":"","class":"media-image","id":"media_crop_2267695732289","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"393","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
[[{"type":"media","view_mode":"media_crop","fid":"12234","attributes":{"alt":"","class":"media-image","id":"media_crop_8355182609789","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"394","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
Findings:
1. Multiple subpleural areas of honeycombing with cystic spaces outlined by thick fibrous walls, with basal predominance
2. Patchy areas of interlobular septal thickening interspersed with areas of ground glass opacities and normal lung parenchyma
3. Bilateral areas of traction bronchiectasis due to interstitial fibrosis along with architectural distortion of the secondary pulmonary lobule
4. Mild mediastinal lymphadenopathy
Differential diagnosis to be considered are usual interstitial pneumonia and idiopathic pulmonary fibrosis. Histology confirmed the diagnosis of usual interstitial pneumonia/idiopathic pulmonary fibrosis.
The disease maybe complicated by bronchogenic carcinoma. Prognosis is usually poor with only 10 percent to 15 percent of cases responding to steroids, with an average survival of three to six years.
Ankur Wadhera, MD
Resident, Department of Radiodiagnosis, Christian Medical College, Ludhiana.
Punjab, India
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.